Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BURNS J. J., YU T. F., RITTERBAND A., PEREL J. M., GUTMAN A. B., BRODIE B. B. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther. 1957 Mar;119(3):418–426. [PubMed] [Google Scholar]
- KERSLEY G. D., COOK E. R., TOVEY D. C. Value of uricosuric agents and in particular of G. 28 315 in gout. Ann Rheum Dis. 1958 Sep;17(3):326–333. doi: 10.1136/ard.17.3.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- LANSBURY J., HAUT D. D. Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity. Am J Med Sci. 1956 Aug;232(2):150–155. [PubMed] [Google Scholar]
- OGRYZLO M. A., HARRISON J. Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis. 1957 Dec;16(4):425–437. doi: 10.1136/ard.16.4.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SEEGMILLER J. E., GRAYZEL A. I. Use of the newer uricosuric agents in the management of gout. JAMA. 1960 Jul 9;173:1076–1080. doi: 10.1001/jama.1960.03020280016004. [DOI] [PubMed] [Google Scholar]
- YU T. F., BURNS J. J., GUTMAN A. B. Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum. 1958 Dec;1(6):532–543. doi: 10.1002/art.1780010606. [DOI] [PubMed] [Google Scholar]